Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Factors associated with increased mortality in AMD

05 Dec 2017

Survival in age-related macular degeneration (AMD) may be reduced in patients with late disease, bilateral cataract surgery and poor visual acuity, according to data from the Age-Related Eye Disease Study 2 (AREDS2). Moreover, oral supplementation with omega-3 fatty acids, lutein plus zeaxanthin, zinc or beta-carotene does not significantly affect mortality.

AREDS2 randomized 4,203 patients with at least intermediate AMD to receive lutein/zeaxanthin and/or omega-3 fatty acids for treatment of AMD and cataract. Baseline and annual assessments included best-corrected visual acuity (BCVA), slit-lamp examinations and stereoscopic fundus photographs that were centrally graded for development of late AMD (central geographic atrophy or neovascular AMD) or pseudophakia.

Of the patients, 368 died during a median follow-up of 5 years. In Cox proportional hazards models, mortality was elevated in patients with neovascular AMD in one eye at baseline than in those with no or few drusen (hazard ratio [HR], 1.56; 95 percent CI, 1.21 to 2.01; p<0.001).

Survival was also poor for patients with bilateral cataract surgery before enrolment than for those with baseline bilateral phakia (HR, 1.63; 1.29 to 2.07; p<0.001), as well as for patients with BCVA of <20/40 vs those with ≥20/40 (HR, 1.56; 1.06 to 2.30; p=0.024).

On the other hand, mortality was lower in patients who received antivascular endothelial growth factor therapies for neovascular AMD than in those who did not (HR, 0.71; 0.57 to 0.88; p=0.002).

The association between all-cause mortality and AREDS2 treatment did not significantly differ whether assessing the main or individual treatment effect (omega-3 fatty acids main effect: HR, 1.18; 0.96 to 1.45; p=0.12; lutein/zeaxanthin main effect: HR, 1.04; 0.85 to 1.28; p=0.71).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.